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Introduction
In humans, active HIV-1 replication in the bone marrow 
(BM) has been suggested based on reports that the viral load 
was very similar to the viral load in the blood, in terms of both 
cell-free1 and cell-associated virus.2 Within BM cell subpop-
ulations, CD34+ hematopoietic progenitor cells express the 
HIV-1 receptor CD4 and low levels of the coreceptor 
CXCR43 and have been reported to be susceptible to HIV-1 
infection in vitro with varying efficiency.4,5 Several investiga-
tors have shown that receptor and coreceptor expression cor-
relates with the susceptibility of progenitor cells to HIV-1.4,6–9 
Therefore, it is likely that physiological events that elevate 
levels of CXCR4 facilitate infection of progenitor cells by 
increasing the net availability of the coreceptor at the cell sur-
face. It has been reported that cyclic adenosine monophos-
phate (cAMP)-dependent upregulation of CXCR4 in human 
T-lymphocytes is mediated by a cAMP-responsive element 
(CRE) in the 5′ untranslated region (UTR) of its promoter.10 
Therefore, it was of interest to determine whether a similar 
cAMP induction would augment CXCR4 levels and HIV-1 
infection in BM progenitor cells using quantitative real-time 
polymerase chain reaction (qRT-PCR) and in vitro viral 
replication assays. The specific adenylyl cyclase (AC) activator 
forskolin was used to augment intracellular cAMP levels in 
the CD34+CD4+CXCR4+ human BM progenitor cell line 
TF-1. Interestingly, we have previously identified a CRE 
sequence upstream of the transcription start site in the 
U3 region of the HIV-1 promoter (designated the long 
terminal repeat [LTR]), and this cis–acting element 
(TGCTGACATCGAGC)11 was shown to interface with 
many members of the ATF (activating transcription factor)/
CREB (cAMP response element binding protein) family 
of transcription factors. We also investigated the effects of 
cAMP accumulation on transcription driven by the LAI (X4-), 
YU2 (R5-), and 89.6 (X4/R5-) HIV-1 LTRs in TF-1 cells 
using a transient expression system. Electrophoretic mobility 
shift (EMS) assays were performed to identify the presence of 
CREB-1, the primary cAMP-responsive transcriptional acti-
vator,12 in molecular complexes interacting with these CREs. 
The contribution of CREB-1 in mediating the stimulatory 
effects of cAMP on CXCR4 and HIV-1 LTR activity was 
also examined. Because protein kinase A (PKA) has been 
identified as the primary effector of CREB-1 activation in 
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TF-1 cells, its role in facilitating cAMP-mediated effects was 
also studied. Based on these results, it was hypothesized that 
the cAMP-PKA-CREB-1 pathway represents a common 
underlying mechanism involved in upregulating HIV-1 
LTR-directed transcription and CXCR4 expression in BM 
progenitor cells, resulting in increased HIV-1 infection.
Materials and methods
Reagents
Forskolin (Sigma-Aldrich), a diterpene obtained from Coleus 
forskohlii, was used to elevate intracellular cAMP concentra-
tions in TF-1 cells. The PKA-specific inhibitor H-89 was also 
obtained from Sigma-Aldrich. Lysis buffers for nuclear extract 
preparation were treated with Protease Inhibitor Cocktail Set 
III and Phosphatase Inhibitor Cocktail Set II, which were 
obtained from Calbiochem. Total cellular RNA for TaqMan 
qRT-PCR was prepared from TF-1 cells using TRI Reagent 
(Sigma-Aldrich).
Cell culture and treatment procedures
The TF-1 CD34+CD38+ cell line (American Type Culture 
Collection [ATCC]) was grown in Roswell Park Memorial 
Institute (RPMI) 1640 medium (ATCC) supplemented with 
10% heat-inactivated fetal bovine serum (HyClone), penicillin 
(100 U/mL), streptomycin (100 µg/mL), and recombinant 
human granulocyte/macrophage colony-stimulating factor (2 
ng/mL; eBioscience) and maintained at 37°C in 5% CO2 at 
90% relative humidity.
Cloning and site-directed mutagenesis
The HIV-1 LAI, YU2, and 89.6 LTRs were cloned into 
the pGL3-Basic vector (Promega) with the firefly luciferase 
(luc) gene. The LAI-LTR-Luc, YU2-LTR-Luc, and 89.6 
LTR-Luc reporter constructs have been described previ-
ously.13,14 Site-directed mutagenesis was performed using 
the QuikChange mutagenesis procedure (Stratagene) on all 
three HIV-1 LTR-Luc reporter vectors to incorporate a TG 
mutation in the ATF/CREB site that is reported to exhibit a 
knockout phenotype with respect to binding CREB-1 (Santa 
Cruz Biotechnologies). The following primers were used 
for site-directed mutagenesis: LAI-LTR (5′-CAA-GAA-
CTG-CTG-TGA-TCG-AGC-TTG-CT-3′), YU2-LTR (5′-CAA-GAA-CTG- 
ATG-TGC-TCG-AGC-TTT-CT-3′), and 89.6 LTR 
( 5 ′ - AC T - G A A - C T G - C T G -T G A - C T G - AG C -
TAT-CT-3′). Sequences were confirmed and analyzed using 
Lasergene software (DNASTAR, Inc.).
Transient transfections and expression analyses
TF-1 cells (2 × 106) were transiently transfected with 
the HIV-1 parental or mutated TG firefly luciferase-LTR 
constructs (1 µg) in conjunction with the pRL-TK Renilla 
luciferase (Promega) internal control vector (50 ng) or a com-
bination of wild-type luciferase-LTR constructs, pRL-TK, and 
CREB-133/KCREB vectors (Clontech Laboratories, Inc.) 
using the Amaxa Nucleofector System T procedure (Amaxa). 
After transfection, cells were placed in new media and allowed 
to recover for an hour. Cells were then either left untreated for 
24 hours or pretreated with H-89 (10 µm) for 1 hour followed 
by forskolin stimulation (100 µm) for 24 hours or were treated 
with forskolin alone. Cell extracts were harvested and assayed 
using the Dual-Luciferase Assay procedure as described by the 
manufacturer (Promega). Firefly luminescence was normalized 
to Renilla luminescence to control for variations in transfection 
efficiency. Error bars indicate the standard deviation of the 
results obtained from three independent experiments.
Isolation of RNA and qRT-PCR
TF-1 cells were serum starved for 1 hour and subsequently 
total RNA was isolated from forskolin (100 µm)-treated cells 
every 3 hours for 24 hours using TRI reagent. To confirm the 
role of PKA in cAMP-mediated stimulation of CXCR4, 
cells were pretreated with H-89 (10 µm) for one hour fol-
lowed by forskolin treatment for nine hours and total RNA 
extraction. To implicate CREB-1 in mediating cAMP-
induced CXCR4 transcription, cells were transfected with 
CREB-133/KCREB constructs as indicated earlier, treated 
with forskolin (100 µm) for nine hours following recovery, 
and the total RNA was isolated. Reverse transcription was 
performed using the SuperScript III First-Strand Synthesis 
System (Invitrogen) on 2 µg of total RNA per sample. qRT-
PCR was performed on cDNA samples using TaqMan 
Universal PCR Master Mix and gene expression primer/
probe assays (Applied Biosystems, Inc.) for CXCR4 and for 
human large ribosomal protein (RPLPO), which was exam-
ined as normalization control. Augmentation of mRNA lev-
els in treated samples was analyzed as fold over untreated 
(calibrator) on an ABI 7300 Thermocycler (Applied 
Biosystems) and expressed on a linear scale. All samples were 
assayed in triplicate.
Nuclear extract preparation and EMS assays
Large-scale nuclear extracts were prepared from forskolin-
treated (100 µm) TF-1 cells as described.15 Briefly, low passage 
number, exponentially growing cells (0.5 × 106/mL) were col-
lected by centrifugation, washed with cold phosphate-buffered 
saline (PBS; CellGro), and lysed in ice-cold lysis buffer A by 
homogenizing in a Dounce homogenizer. After centrifugation, 
the supernatant was discarded, and the nuclear pellet was again 
lysed in chilled lysis buffer C by homogenization. After vortex-
ing for 30 minutes at 4°C, centrifugation (14,000 rpm) was 
performed to collect the supernatant. This was dialyzed 
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overnight at 4°C in dialysis buffer, and the concentration of 
protein was determined using the bicinchoninic acid (BCA) 
protein assay procedure from Pierce ECL. Complementary 
single-stranded DNA oligonucleotides (corresponding to 
either parental or mutated TG CRE sequences in LAI, YU2, 
and 89.6 LTRs or CXCR4 5′ UTRs) were obtained from IDT 
Integrated DNA Technologies. After purification of these 
probes by butanol extraction and ethanol precipitation, they 
were annealed by heating at 100°C for 5 minutes and slowly 
cooling to room temperature. Probes were 5′-end labeled using 
T4 DNA kinase (Promega) and [γ-32P] adenosine triphos-
phate (ATP) at 37°C. Labeled probes (75,000 cpm/lane) were 
incubated with 2 µg of nonspecific DNA (poly(dI-dC) Roche) 
and 12 µg of forskolin-treated nuclear extract at 30°C for 15 
minutes. Supershift analyses were performed by incubation of 
the complexes for another 15 minutes with CREB-1-specific 
antibody (sc-186x; Santa Cruz Biotechnologies) or an iso-
type-matched control antibody (Santa Cruz Biotechnologies). 
DNA–protein complexes were resolved on 5% nondenaturing 
polyacrylamide gels at 200 V at 4°C for approximately three 
hours. Gels were dried at 80°C for one hour and subjected to 
autoradiography.
HIV-1 p24 ELISA
Cells were seeded into 12-well plates at a density of 0.5 × 106 
cells/mL and incubated for 24 hours in the absence or presence 
of forskolin (100 µm). Cells were then recounted and seeded at 
a concentration of 1 × 106 cells/mL/well. This was followed by 
exposure to the CXCR4-utilizing HIV-1 IIIB strain at a titer 
of 105 TCID50 (50% tissue culture infective dose) (Advanced 
Biotechnologies, Inc.). After 2 hours, cells were washed with 1 
× PBS, resuspended in fresh RPMI 1640 media and reseeded 
in 12-well plates for 24 hours. Supernatant was collected 
and assayed for HIV-1 p24 core antigen using an Alliance 
p24 enzyme-linked immunosorbent assay ELISA procedure 
(Perkin Elmer). All samples were assayed in triplicate.
Results
Identif ication of CREs in the HIV-1 LTR and 
CXCR4 5′ UTR
The LAI, YU2, and 89.6 HIV-1 LTR sequences were obtained 
from the Los Alamos Sequence Database (GenBank accession 
numbers X01762, M93258.1, and U39362.2, respectively). The 
CXCR4 promoter-5′ UTR sequence was previously published 
(GenBank accession ID AJ224869.1).16 Analysis of these 
sequences using the online transcription factor binding site 
software Match from the TRANSFAC 7 public database 
(www.gene-regulation.com) identified the presence of a single 
CRE in the entire CXCR4 promoter-5′ UTR (+23 to +30) and 
in the HIV-1 LTR located upstream of the transcription start 
site (−118 to −127) by adopting a stringent cutoff ratio (matrix 
similarity = 0.8, core similarity = 0.85) (Figure 1A).
Effects of intracellular cAMP augmentation on 
LTR-directed transcription
Forskolin, a diterpene obtained from C. forskohlii, is a potent 
and specific activator of AC and was used to elevate intracel-
lular cAMP levels in TF-1 cells. Transient transfection assays 
were utilized to measure LTR-driven firefly luciferase gene 
expression as a direct measure of HIV-1 LTR activation. 
Titration of transfected TF-1 cells with increasing concentra-
tions of forskolin exhibited a dose-dependent increase in 
HIV-1 LAI, YU2, and 89.6 LTR activity. After the results were 
normalized to Renilla luciferase expression and plotted as fold 
over untreated samples, it was apparent that the HIV-1 LAI-
LTR was the most inducible (6.2-fold), the YU2-LTR was 
intermediate (2.9-fold), and the 89.6 LTR was the least (1.9-
fold) (Figure 1B). This differential responsiveness was pro-
posed to be a reflection of the variation in the genetic sequence 
of the respective CREs specifically and the LTR in general.
Site-directed mutagenesis of the HIV-1 LAI-, YU2-, and 
89.6 LTR-luc constructs to incorporate an AC to TG mutation 
in the first half of the CRE site in conjunction with transient 
transfections exhibited an abrogation in activity of these LTRs 
in response to forskolin. After the results were normalized to 
Renilla luciferase expression and compared with basal LTR 
activity, the fold change of 100 µm forskolin-stimulated paren-
tal LTR-luc levels (LAI, 6.1; YU2, 2.9; 89.6, 1.8) and forsko-
lin-stimulated TG LAI-LTR (1.17), YU2-LTR (0.49), and 
89.6 LTR (0.69) were plotted that showed that LAI and YU2 
activity was diminished most in comparison with 89.6 (Figure 
1C), reiterating the absolute requirement for the CRE site for 
facilitating cAMP-induced LTR-directed transcription.
Kinetics of cAMP-induced CXCR4 transcription 
in TF-1 cells
qRT-PCR assays were performed to study the regulation of 
CXCR4 transcription in response to enhanced cAMP levels 
(Figure 1D). Kinetics revealed a biphasic curve, wherein tran-
script levels always remained elevated and returned close to the 
untreated threshold level only at 24 hours after forskolin stim-
ulation. The amplitude of the curve was observed at 6–9 hours 
(4-fold increase), with transcript levels declining at 15 hours 
(1.92-fold). Subsequently, a smaller peak was observed at 
18 hours (2.8-fold). These results suggest functional signifi-
cance of the CRE with respect to mediating cAMP-induced 
CXCR4 transcription. The biphasic nature of the response to 
forskolin is a likely outcome of the kinetics and dynamics rela-
tive to the interaction of cognate transcription factors with the 
LTR-specific CRE.
Binding of CREB-1 to identif ied CREs in vitro in 
TF-1 cells
To analyze the molecular basis of cAMP-induced transcription 
mediated by the CREs in HIV-1 and CXCR4 promoter/UTR, 
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EMS assays were performed to detect the presence of the tran-
scription factor CREB-1 in complexes formed between forsko-
lin-stimulated TF-1 nuclear extracts and radiolabeled parental 
and TG-mutated oligonucleotides (Figure 2). Compared with 
the “probe-only” reaction (lane 1), a specific DNA–protein 
complex was detected in the case of (A) LAI, (B) YU2, (C) 89.6, 
and (D) CXCR4 parental CRE probes (lane 2). This complex 
consisted of three distinct bands (asterisk) that exhibited either 
abrogation (Figure 2B and C) or a combination of both abroga-
tion and supershift (Figure 2A and D) when the reaction was 
incubated with a CREB-1-specific antibody (lane 4). Addition 
of an isotype antibody did not affect the complex (lane 3). The 
upper two bands likely represent the 43-kDa ubiquitous phos-
phorylated CREB-1-α,Δ activator isoforms,12 whereas the 
lower band is most likely the homologous family member phos-
phorylated ATF-1. Incubation with mutant TG oligonucleo-
tides prevented the formation of the CREB-1 complex, 
indicating the likely involvement of CREB-1 in binding and 
activation of the identified CREs.
Involvement of CREB-1 in CXCR4 and HIV-1 
LTR-directed transcription in TF-1 cells
Transient transfection assays with dominant-negative 
CREB-1 constructs were employed to definitively implicate 
CREB-1 in cAMP-induced HIV-1 LTR activation. The 
KCREB construct (pKCREB) encodes a form of CREB-1 
with mutations in its DNA-binding domain. The inability to 
bind CRE results in mutant CREB-1 acting as a dominant-
negative repressor, blocking cAMP-induced transcription. 
The CREB-133 construct (pCREB-133) also encodes a 
mutated form of CREB, preventing Ser133 CREB-1 phos-
phorylation required for transactivation, thereby blocking 
cAMP-induced transcription.
In comparison with forskolin-stimulated cells transfected 
with parental LTR-luc constructs and empty vector, cells trans-
fected with LTR-luc and CREB-133 or KCREB constructs 
exhibited diminution in firefly luciferase expression (Figure 3A). 
In the case of LAI, absolute expression decreased from 1 (arbi-
trarily set for LAI-LTR-luc) to 0.27 (LAI-LTR-luc + KCREB) 
and 0.32 (LAI-LTR-luc + CREB-133). In the case of YU2, 
absolute expression decreased from 1 (arbitrarily set for YU2-
LTR-luc) to 0.68 (YU2-LTR-luc + KCREB) and 0.56 (YU2-
LTR-luc + CREB-133). In the case of 89.6, absolute expression 
decreased from 1 (arbitrarily set for 89.6 LTR-luc) to 0.38 (89.6 
LTR-luc + KCREB) and 0.54 (89.6 LTR-luc + CREB-133). 
As observed in Figure 1 with TG-mutated CREs, the LAI-LTR 
is the most susceptible LTR with respect to inhibition by the 
dominant-negative CREB-1. However, in contrast to earlier 
observations, it is unclear why YU2 is less susceptible to 
Figure 1. Forskolin induces transcriptional activation of HIV-1 LTR and upregulation of CXCR4. (A) The molecular sequence of CREs in the LTR of 
reference HIV-1 strains and in the 5′ UTR of the CXCR4 gene. TRANSFAC analysis identifies the presence of a lone CRE in the CXCR4 promoter-5′ UTR 
and the HIV-1 LTRs. The sequences are compared with a classical consensus CRE in the T-lymphocyte SH2D2A promoter, and the variant base pairs are 
marked in red. (B) With forskolin stimulation (the range of concentrations included 0, 10, 25, 50, 75, and 100 µm), the HIV-1 LTRs are activated and drive 
luciferase gene expression to different extents. The LAI-LTR was the most inducible (6.2-fold), followed by the YU2-LTR (2.9-fold) and the 89.6 LTR 
(1.9-fold). (C) After site-directed mutagenesis of LTR-luc constructs, the activity of 100 µm forskolin-stimulated TG LAI-LTR, YU2-LTR, and 89.6 LTR was 
reduced by 81%, 83%, and 64%, respectively. (D) The biphasic curve of CXCR4 transcription in response to 100 µm forskolin is characterized by an initial 
peak at 6–9 hours (4-fold upregulation) followed by a trough at 15 hours (1.92-fold upregulation) and a smaller peak at 18 hours (2.8-fold upregulation) 
after stimulation. Although transcript levels declined at 15 hours, they remained elevated in comparison with untreated samples. Results are normalized to 
RPLPO expression and expressed in linear scale as fold over untreated. Asterisks indicate significance of P < 0.05 using Student’s t–test.
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dominant-negative CREB-1 in comparison with 89.6. In the 
case of LAI, the difference may be partly explained by an abso-
lute requirement for CREB-1-CRE complex formation. We 
speculate that, in the case of YU2 and 89.6, other transcription 
factors and sequences adjacent to the HIV-1 LTR CRE may 
also play a role in facilitating cAMP-induced LTR activation.
qRT-PCR assays with dominant-negative CREB-1 con-
structs were similarly used to reinforce the involvement of 
CREB-1 in CXCR4 transcription. In comparison with 
untransfected forskolin-treated samples, both pKCREB and 
pCREB-133 transfected samples showed 2-fold decline in 
levels of CXCR4 mRNA at nine hours after forskolin treat-
ment. In the case of untransfected untreated samples, this 
decline was a little more pronounced (Figure 3B). As 
expected, transcription was not suppressed completely due 
to the presence of endogenous CREB-1 and other tran-
scription factor isoforms belonging to the ATF/CREB fam-
ily in TF-1 cells.
Figure 2. CREB-1 is present in the DNA–protein complexes formed between forskolin-stimulated TF-1 nuclear extracts and identified CREs. EMS assays 
performed with forskolin-stimulated TF-1 nuclear extracts and radiolabeled probes corresponding to (A) LAI, (B) YU2, (C) 89.6, and (D) CXCR4 parental 
CREs revealed the presence of CREB-1 43-kDa protein in the DNA–protein complex (asterisk). Although the complex was unaffected by an isotype 
antibody, it was abrogated/supershifted with a CREB-1-specific antibody. Corresponding reactions with mutant TG CRE radiolabeled oligonucleotides 
exhibit the absence of the CREB-1-containing complex, suggesting that CREB-1 directly binds to parental CREs in vitro. Two other DNA–protein 
complexes (double and triple asterisks) are also present and are nonspecific in nature as they remain unaffected by addition of specific antibody.
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Effects of PKA inhibition on cAMP-induced 
CXCR4 and HIV-1 LTR-directed transcription
We have previously identified PKA as a primary facilitator of 
CREB-1 phosphorylation in TF-1 cells in response to cAMP 
augmentation.17 Therefore, to implicate PKA as a key interme-
diary in the linear pathway from cAMP to CREB-1, transient 
transfections and qRT-PCR experiments were performed, 
assaying for firefly luciferase expression and CXCR4 mRNA 
levels, respectively, in the absence or presence of the PKA 
inhibitor H-89.
The forskolin-stimulated HIV-1 LAI-, YU2-, and 89.6 
LTR-luc expression levels were consistent with those observed 
in Figure 1B. However, the result obtained with the 89.6 LTR 
was not shown to be statistically significant due to the larger 
error in this experiment. In the presence of H-89 alone, there 
was a marginal reduction, although not statistically significant, 
with respect to basal LTR-luc levels. This is probably due to 
the fact that CREB normally plays a role in transactivating the 
LTR under basal conditions. So inhibiting PKA from phos-
phorylating CREB under basal conditions can and probably 
should still have some effect. In the case of forskolin stimula-
tion, H-89 pretreatment completely abrogated luciferase 
expression from all three HIV-1 promoters (Figure 4A). This 
result confirmed the presence of PKA as the immediate effec-
tor of cAMP and suggested that PKA inhibition obliterates, in 
part, downstream activation of CREB-1, thereby abolishing 
cAMP-induced transcription.
Similarly, forskolin-stimulated CXCR4 mRNA levels were 
consistent with those observed in Figure 1D. In comparison 
with untreated samples, there was a maximum upregulation at 
nine hours (4.6-fold). After pretreatment with H-89, this 
upregulation was inhibited by 50% (2.3-fold). H-89 treatment 
alone did not significantly affect basal CXCR4 mRNA levels 
(Figure 4B). In contrast to HIV-1 LTR activity, this suggested 
only partial dependence of CXCR4 transcription on PKA. 
Figure 3. cAMP-induced transcriptional activation of HIV-1 and CXCR4 
promoters is specifically mediated by CREB-1. (A) In comparison with 
forskolin-stimulated cells transfected with parental LTR-luc constructs 
alone, cells with LTR-luc and CREB-133 or KCREB constructs exhibit 
diminution in firefly luciferase expression. All firefly luciferase readings 
were normalized to Renilla readings by cotransfecting cells with the 
pRL-TK Renilla luciferase construct and expressed as ratios of forskolin-
treated to untreated samples. (B) qRT-PCR assays revealed that in 
comparison with untransfected untreated and untransfected forskolin-
treated samples, pKCREB and pCREB-133 transfected samples showed 
diminution in CXCR4 transcript levels. Results were normalized to 
RPLPO expression and expressed in linear scale as fold over untreated 
untransfected samples. Asterisks indicate significance of P < 0.05 using 
Student’s t–test.
Figure 4. Increased cAMP-induced expression from HIV-1 and CXCR4 
promoters is facilitated by PKA. (A) In comparison with untreated 
samples, forskolin-stimulated cells exhibit up to a ~6-fold upregulation in 
luciferase expression. This upregulation is completely inhibited by H-89 
pretreatment for one hour. H-89 alone slightly diminishes basal luciferase 
expression. All firefly luciferase readings were normalized to Renilla 
readings by cotransfecting cells with the pRL-TK Renilla luciferase 
construct and expressed as fold over untreated samples. (B) qRT-PCR 
assays revealed that in comparison with untreated samples, forskolin-
treated samples showed a ~4.6-fold increase in CXCR4 transcript levels. 
This was reduced by 50% when samples are pretreated with H-89. 
Results were normalized to RPLPO expression and expressed in linear 
scale as fold over untreated samples. Asterisks indicate significance of P 
< 0.05 using Student’s t–test.
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This result was consistent with our previous experiments 
wherein CREB-1 phosphorylation was not completely abol-
ished after PKA inhibition,17 indicating the likely role of other 
kinases in mediating this effect.
Effects of cAMP augmentation on HIV-1 
replication in TF-1 cells
To understand if forskolin upregulation of CXCR4 in TF-1 
cells resulted in increased virus infection, viral infectivity assays 
were performed using a CXCR4-utilizing HIV-1 strain IIIB. 
These experiments revealed an increase in replication (3.3-
fold) of the HIV-1 strain IIIB in response to forskolin treat-
ment (Figure 5). Along with the results obtained from LTR 
activation experiments, these results suggested that increased 
CXCR4 levels might translate into increased viral entry and 
subsequent replication based on the observed increase in LTR-
directed transcription. Additional experiments will assess 
the presence of unspliced and multiple spliced transcripts to 
confirm this observation.
Discussion
Because HIV-1 has been reported to be present in the BM of 
HIV-1-infected patients, it is likely that CD34+CD4+CXCR4+ 
BM progenitor cells are susceptible to infection by at least a 
subset of HIV-1 viral strains. However, BM stromal cells pro-
duce in vivo large quantities of stromal cell-derived factor-1α 
(SDF-1α), a member of the family of α-chemokines and the 
only natural and endogenous ligand of CXCR4.18 CD34+CD38+ 
BM progenitors have also been reported to be positive for 
SDF-1α.3 More importantly, SDF-1α competes with CXCR4-
utilizing HIV-1 with respect to binding to the coreceptor 
CXCR4,19 blocking HIV-1 entry,18 and productive infection.20 
Therefore, progenitors are assumed to be partially refractile to 
infection in vivo. In this scenario, competition for occupation 
of CXCR4 by HIV-1 can be modulated by either a decline in 
SDF-1α production or an augmentation in levels of the core-
ceptor itself. Because cAMP has been reported to increase 
CXCR4 transcript levels in T-lymphocytes owing to the pres-
ence of a CRE,10 it was of interest to determine whether a 
similar phenomenon would apply to BM progenitor cells. This 
would then relate to the potential of BM progenitor cells being 
more susceptible to HIV-1 due to the increased CXCR4 
expression on the cells. Secondarily once integrated in the cell 
cAMP could also induce the LTR compounding the infection 
by driving more viral transcription and hence replication. The 
in vivo significance of this question is not lost as patients with 
late-stage HIV-1 infection exhibit very high circulating levels 
of prostaglandin E2,21 a natural cAMP-inducing ligand. For 
our studies, the well-characterized CD4+CXCR4+ human 
BM progenitor cell line TF-1 and the cAMP-enhancing 
AC-activator forskolin were selected for use in the experimen-
tal design. A biphasic wave of induction was observed in 
CXCR4 transcription in TF-1 cells. We also determined 
whether elevated cAMP levels would affect HIV-1 promoter 
activity, given that we have previously identified a CRE in the 
HIV-1 LTR.11 The presence of a single CRE in the LTRs of 
LAI, YU2, and 89.6 strains was detected by TRANSFAC 
analyses by comparison with a consensus CRE. In addition to 
the structural differences among the CREs in the LTRs of the 
individual HIV-1 strains, these elements were observed to be 
different from the CRE present in the CXCR4 5′ UTR. These 
genetic alterations are likely to affect the responsiveness of 
these genes to a cAMP stimulus due to the potential for dif-
ferential recruitment of cAMP-responsive transcription factors 
to CREs with different sequence variants. This possibility was 
reiterated in transient transfection assays wherein the LAI-
LTR was found to be most inducible in comparison with the 
YU2 and 89.6 promoters. Moreover, the cAMP response was 
found to be directly mediated by the identified CRE as appar-
ent from site-directed mutagenesis studies. qRT-PCR and 
Figure 5. Forskolin treatment enhances replication of the CXCR4-
utilizing HIV-1 strain IIIB in TF-1 cells. Assays for HIV-1 p24 were 
performed on cellular supernatants 24 hours after infection to assess 
HIV-1 IIIB replication in response to 100 µm forskolin treatment in TF-1 
cells. The Y–axis denotes fold increase in p24 levels over untreated 
samples. Forskolin-treated (24 hours) TF-1 cells exhibit a ~3.3-fold 
increase in p24 levels.
Figure 6. The cAMP-PKA-CREB-1 pathway in TF-1 cells. Forskolin 
treatment enhanced intracellular cAMP levels by directly activating 
membrane-bound AC. This resulted in activation of the PKA catalytic C 
subunits, which diffuse into the nucleus. Once inside, they 
phosphorylated CREB-1 activator isoforms. Activated CREB-1 binds to 
CREs in the HIV-1 and CXCR4 promoter/5′ UTRs, thereby increasing 
transcription. This may have resulted in increased surface levels of 
CXCR4 and an increase in HIV-1 susceptibility.
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transfection analyses also identified PKA and the transcription 
factor CREB-1 as key sequential effectors of this dual-pronged 
stimulation of CXCR4 and HIV-1 LTR-mediated transcrip-
tion. Finally, an observed increase in replication of CXCR4-
utilizing IIIB strain in forskolin-stimulated TF-1 cells 
highlights the utility of these cells as a physiologically relevant 
cellular model (Figure 6) for determining the effects of intra-
cellular cAMP elevation on HIV-1 infection as well as gene 
expression in progenitor cells.
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